1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

 
• By Mandy Jackson

Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.

Cancer-cells-pink-color_1200x675

Bristol-Myers Squibb Co. reported once again that the combination of its blockbuster PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) did not achieve statistical significance in a Phase III clinical trial – at least in terms of progression-free survival – but the ongoing first-line renal cell carcinoma (RCC) trial still could yield significant results in overall survival.

This is the second Phase III disappointment this year for Opdivo plus Yervoy after Bristol revealed in April that the combination did not significantly improve overall survival versus Roche/Genentech Inc.'s VEGF inhibitor Avastin (bevacizumab) in glioblastoma multiforme (GBM) – one of the hardest to treat cancers. (Also see "Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline" - Scrip, 7 April, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.